Navigation Links
Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results
Date:7/29/2008

366) $(34,471)

Basic and diluted net

loss per share: ($0.34) ($0.41) ($0.70) ($0.61)

Shares used in

calculation of basic

and diluted net loss

per share: 56,359 56,170 56,316 56,148

(1) Stock-based compensation expenses included in operating expenses

amounted to approximately:

Research and development $467 $723 $1,127 $1,891

Selling, general and

administrative 876 1,296 1,755 2,533

IDENIX PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(IN THOUSANDS)

(UNAUDITED)

June 30, December 31,

2008 2007

ASSETS

Cash and cash equivalents $ 54,062 $ 48,260

Marketable securities 16,270 39,862

Receivables from related party 1,727 11,196

Other current assets 3,221 4,401

Total current assets 75,280 103,719

Intangible asset, net 12,968 13,548

Property and equipment, net 14,873 15,460

Marketable securities, non-current 10,308 23,882

Other assets 3,852 3,931

Total assets $ 117,281 $ 160,540

LIABILITIES AND STOCKHOLDERS' EQUITY

Accounts payable and accrued expenses $ 15,953 $ 21,809

Deferred revenue, related party 7,766 8,372

Other current liabilities 64
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Idenix Pharmaceuticals to Present at the Seventh Annual Needham and Company, LLC Biotechnology and Medical Technology Conference
2. Idenix Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
3. Idenix Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
4. Idenix Announces Data Presentations at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL)
5. Idenix to Host Conference Call Discussing Fourth Quarter 2007 Financial Results
6. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
7. Idenix to Host Conference Call Discussing Third Quarter 2007 Financial Results
8. Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
9. Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31
10. Sagent Pharmaceuticals Launches Ceftazidime for Injection, USP
11. Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Sept. 19, 2014  Nektar Therapeutics (NASDAQ: ... studies characterizing the analgesic profiles of a series ... receptor agonist molecules. The preclinical research candidates were ... platform. The analgesic properties of kappa ... literature. 1,2 Kappa opioid receptors are expressed ...
(Date:9/19/2014)... September 19, 2014 Barnhardt Manufacturing ... Label for its Organic Cotton . The USDA ... of renewable biobased ingredients meets or exceeds levels set ... composed in whole or in significant part of agricultural, ... allow our Organic cotton to be immediately identified as ...
(Date:9/19/2014)... ROCKLAND, Massachusetts , September 19, 2014 ... with the 53rd European Society for Paediatric Endocrinology (ESPE) ... advancement of science and medical research in the field ... of Merck KGaA, Darmstadt, Germany , ... Growth Innovation (GGI) for 2014. The awards were announced ...
(Date:9/18/2014)... TX (PRWEB) September 18, 2014 ... integrated urological and interventional radiology products and services, ... known as cryotherapy and cryoablation) versus external beam ... Section of the American Urological Association (MAAUA) Annual ... , "Comparing Relative Effectiveness of Cryosurgery and External ...
Breaking Biology Technology:Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5Barnhardt Manufacturing Company Earns USDA Certified Biobased Product Certification and Label for Organic Cotton 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2
... and Webcast on May 9 at 8:00 a.m. PDT ... Inc.,(Nasdaq: HALO ), a biopharmaceutical company developing and ... the three months ended March 31, 2008., "This ... significantly advanced both,our partnered and proprietary programs in the ...
... May 8 Telik, Inc. (Nasdaq:,TELK) today reported a ... for,the first quarter ended March 31, 2008, compared with ... for the comparable period in 2007., For the ... were $10.6 million, compared with $18.0 million during the ...
... to ever increasing,cardiac toxicity found in market drugs, Gwathmey ... Cardionomics(TM) services,and the formation of its Cardionomics(TM) Advisory Board ... of drug candidates., Cardiac toxicity has played a ... over the past 30 years. It is estimated that ...
Cached Biology Technology:Halozyme Therapeutics Reports 2008 First Quarter Financial Results 2Halozyme Therapeutics Reports 2008 First Quarter Financial Results 3Halozyme Therapeutics Reports 2008 First Quarter Financial Results 4Halozyme Therapeutics Reports 2008 First Quarter Financial Results 5Halozyme Therapeutics Reports 2008 First Quarter Financial Results 6Halozyme Therapeutics Reports 2008 First Quarter Financial Results 7Halozyme Therapeutics Reports 2008 First Quarter Financial Results 8Halozyme Therapeutics Reports 2008 First Quarter Financial Results 9Telik Announces First Quarter 2008 Financial Results 2Telik Announces First Quarter 2008 Financial Results 3Increased Drug Related Cardiac Toxicity Leads Gwathmey Preclinical Testing Services to Create Novel Cardionomics(TM) Services for Preclinical Cardiac Safety Screening of Drug Candidates 2Increased Drug Related Cardiac Toxicity Leads Gwathmey Preclinical Testing Services to Create Novel Cardionomics(TM) Services for Preclinical Cardiac Safety Screening of Drug Candidates 3Increased Drug Related Cardiac Toxicity Leads Gwathmey Preclinical Testing Services to Create Novel Cardionomics(TM) Services for Preclinical Cardiac Safety Screening of Drug Candidates 4
(Date:9/19/2014)... evolve for the sake of fairness per se but ... so say Frans de Waal, PhD, and Sarah Brosnan, ... (IA), which is defined as a negative reaction to ... . , Their conclusion comes after the co-authors ... hypothesis that it is the evolution of forestalling partner ...
(Date:9/19/2014)... -- Nxt-ID, Inc. (Nasdaq: NXTD and NXTDW) ("Nxt-ID" ... m-commerce market, updates the "Wocket in Your Pocket" celebrity ad campaign, ... middleweight weight classes, Vinny Pazienza (PAZ). ... of Thrones actor Ciaran Hinds and Sons ... Katey Sagal have been cast in Bleed for This ...
(Date:9/18/2014)... Wash. - Washington State University researchers have developed a ... to power waste cleanup in rural areas. , ... to an inexpensive and quick way to clean up ... plants while reducing pollution. , Professor Haluk Beyenal ... of Engineering and Architecture discuss the system in the ...
Breaking Biology News(10 mins):Evolution of responses to (un)fairness 2Evolution of responses to (un)fairness 3NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 2NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 3Researchers develop unique waste cleanup for rural areas 2
... over face threats on many fronts: pollution, diseases, destructive fishing ... resistant to one potential menace seaweed than previously ... scientists from the United States and Australia. Their study ... individual reefs in all, more than 3,500 examinations of ...
... different species are likely to respond to climate change. ... species and the interactions between species, in the interest ... BioScience , by Eric Post of Pennsylvania State ... be avoided. Their approach, which relies on multi-stage analyses ...
... (June 1, 2009) The International Serious Adverse Events ... designed to discover genetic markers that may predict individuals ... The SAEC is a nonprofit research corporation, launched ... by 10 leading pharmaceutical companies and the Wellcome Trust. ...
Cached Biology News:In the turf war against seaweed, coral reefs more resilient than expected 2International Serious Adverse Events Consortium announces initial study results in its global research collaboration to identify genetic markers related to drug induced liver injury 2International Serious Adverse Events Consortium announces initial study results in its global research collaboration to identify genetic markers related to drug induced liver injury 3
... scale-up, these culture chambers produce cell yields ... range and are useful alternatives to ... High mechanical • strength and structural integrity ... • Certified nonpyrogenic and sterilized by gamma ...
Mouse monoclonal antibody to QARS - glutaminyl-tRNA synthetase...
... thermostable DNA polymerase obtained by high level ... in E. coli, Concentration: 5U/ul, Applications: Standard ... Scientific, the world leader in serving science. ... the world healthier, cleaner and safer by ...
ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli....
Biology Products: